32 completed, 6 active not recruiting, 6 recruiting, 6 terminated. 27 Phase 2, 15 Phase 1, 7 Phase 3, 6 Not applicable.
Follow Cervical Adenocarcinoma: new trials by email Literature Review of Cervical Adenocarcinoma trials Research Report on Cervical Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility Study of Blood Biomarker Identification in Cervical Cancer Blood Sample Collection, cfDNA and Extracellular Vesicle Biomarker Analysis, Patient-Reported Outcome and Quality-of-Life Assessment - Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma | Recruiting | Queensland Centre for Gynaecological Cancer | 100 | 2026-09-15 | 2026-09-02 | |
| AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors AVA6103 - Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Avacta Life Sciences Ltd | 174 | 2026-03-31 | 2026-10-05 |
| Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda Hypofractionated Radiation Therapy, Conventional Fractionated Radiotherapy, Cisplatin - Cervical Cancer, Cervix Cancer | Phase 2 | Recruiting | Uganda Cancer Institute | 278 | 2026-03-11 | 2026-03-27 |
| QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy QL1706 (bispecific antibody targeting PD-1 and CLTA-4) - Cervical Cancer, Cervical Cancer Metastatic | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 50 | 2025-10-01 | 2025-08-26 |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) - Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 150 | 2025-08-22 | 2026-09-17 |
| External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer Bevacizumab, Biospecimen Collection, Brachytherapy - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 35 | 2025-07-29 | 2026-08-12 |
| Effect of Prehabilitation on Recovery Outcomes in Post-Surgical Cervical Cancer Women Structured Prehabilitation Protocol, Conventional - Cervical Adenocarcinoma, Hysterectomy | Not applicable | Completed | Saveetha University | 34 | 2025-06-17 | 2026-07-16 |
| IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial IN10018, Nab-paclitaxel, Cadonilimab - Cervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 25 | 2025-02-17 | 2026-01-13 |
| Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma Pembrolizumab (KEYTRUDA®) - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Not yet recruiting | Gunma University | 45 | 2025-02-01 | 2025-02-03 |
| Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients Rifaximin 550 MG, Standard Care Chemoradiation - Radiotherapy Induced Diarrhea, Acute Radiation Enteritis | Phase 1 / Phase 2 | Not yet recruiting | Mansoura University | 80 | 2025-01-20 | 2025-01-20 |
| RT for Adenocarcinoma/Adenosquamous Carcinoma radiotherapy, Systemic treatment - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Peking Union Medical College Hospital | 60 | 2025-01-01 | 2025-09-04 |
| Primary Cervical Cancer Screening by Self-sampling HPV Test Human Papillomavirus Infection, Cervical Cancer | Active not recruiting | Peking University People's Hospital | 17875 | 2022-11-19 | 2023-12-21 | |
| Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women Carboplatin, Cisplatin, Paclitaxel - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Withdrawn | AIDS Malignancy Consortium | 2022-05-31 | 2022-06-21 | |
| Clinical Evaluation of Detection of High Risk HPV in Urine Human Papillomavirus Infection, Cervical Cancer | Unknown | Peking University People's Hospital | 1000 | 2021-09-15 | 2022-01-27 | |
| Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer Media Intervention, Quality-of-Life Assessment, Questionnaire Administration - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 40 | 2020-03-10 | 2026-07-16 |
| Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Atezolizumab, Brachytherapy, Cisplatin - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2019-01-07 | 2025-11-12 |
| HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma A multi-omics analysis - Cervical Adenocarcinoma, Human Papillomavirus | Unknown | Lei Li | 40 | 2018-11-10 | 2018-11-15 | |
| Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2017-03-10 | 2023-02-21 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Brachytherapy, Cisplatin, External Beam Radiation Therapy - Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 450 | 2016-05-10 | 2026-10-22 |
Showing 20 of 58. Sign in to see all of them.
Uterine Cervical Neoplasms (46) · Neoplasms (3) · Papillomavirus Infections (3) · Uterine Cervical Dysplasia (3) · Vaginal Neoplasms (3) · Vulvar Neoplasms (3) · Adenocarcinoma in Situ (2) · Atypical Squamous Cells of the Cervix (2) · Gestational Trophoblastic Disease (2) · Small Cell Lung Carcinoma (2) · Squamous Intraepithelial Lesions (2) · Adenocarcinoma (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Mucinous (1) · Adrenocortical Carcinoma (1)
Neoplasms by Site (49) · Genital Diseases (48) · Neoplasms (48) · Urogenital Diseases (48) · Female Urogenital Diseases (47) · Female Urogenital Diseases and Pregnancy Complications (47) · Urogenital Neoplasms (47) · Genital Diseases, Female (46) · Genital Neoplasms, Female (46) · Uterine Neoplasms (46) · Uterine Cervical Diseases (45) · Uterine Diseases (45) · Lung Neoplasms (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
Cisplatin (19) · Platinum (13) · 1,2-diaminocyclohexaneplatinum II citrate (12) · Brachytherapy (11) · Taxes (10) · Paclitaxel (8) · Radiation (8) · Bevacizumab (5) · Disulfides (5) · Immunoglobulin G (5) · Radiotherapy (5) · Magnetic Resonance Spectroscopy (4) · Albumin-Bound Paclitaxel (3) · CTLA-4 Antigen (3) · Carboplatin (3)
National Cancer Institute (NCI) (18) · Gynecologic Oncology Group (14) · GOG Foundation (3) · M.D. Anderson Cancer Center (3) · Peking University People's Hospital (2) · AIDS Malignancy Consortium (1) · Advaxis, Inc. (1) · Aktis Oncology, Inc. (1) · Avacta Life Sciences Ltd (1) · Gunma University (1) · Institut de Cancérologie de Lorraine (1) · Jonsson Comprehensive Cancer Center (1) · Lei Li (1) · Mansoura University (1) · Mayo Clinic (1)
United States (42) · Canada (10) · China (7) · Japan (3) · South Korea (3) · Australia (2) · Spain (2) · Argentina (1) · Brazil (1) · Colombia (1) · Egypt (1) · France (1) · Guam (1) · Hong Kong (1) · India (1)
Jyoti S Mayadev (2) · Peter Rose (2) · Alessandro D Santin (1) · Allan L Covens (1) · Amit M Oza (1) · Anna Tinker (1) · Antonio T Fojo, M.D. (1) · Bradley Monk (1) · Cecelia H Boardman (1) · Charles A Leath (1) · Charles Kunos (1) · Charles Levenback (1) · Claire F Friedman (1) · D. McMeekin (1) · Dana M Chase, MD (1)
PMID 19931137, PMID 24395863, PMID 24552320, PMID 25638326, PMID 27998970, PMID 28728751, PMID 28756902, PMID 29163840, PMID 29868473, PMID 31681600, PMID 31871115, PMID 31912685, PMID 31924334, PMID 31969335, PMID 32641240, PMID 32816895, PMID 32847980, PMID 33004542, PMID 33362722, PMID 33882143, PMID 34201380, PMID 34380663, PMID 34716198, PMID 36898292, PMID 37080223, PMID 37650664, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 40947016, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
U10CA027469 (20), U10CA180868 (14), U10CA180830 (2), D43TW009759 (1), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM37008 (1), N01CM62204 (1), P30CA013330 (1), R01CA155454 (1), U10CA021661 (1), U10CA101165 (1), U10CA180821 (1), U10CA180888 (1)